Trials / Completed
CompletedNCT03770013
Dexmedetomidine Versus Clonidine for Transversus Abdominis Plane Block in Patients Undergoing Elective Caesarean Section
Role of Co-administered Dexmedetomidine Or Clonidine With Bupivacaine for Transversus Abdominis Plane Block in Patients Undergoing Elective Caesarean Section: A Randomized, Double-blind Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Aswan University Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Aim to study the efficacy of co-administered Dexmedetomidine Or Clonidine with Bupivacaine and that of bupivacaine 0.25% alone for Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia in Patients Undergoing Elective Caesarean Section. * Group 1: bupivacaine 0.25% + Dexmedetomidine 0.5 mcg/kg (a total volume of 40 ml (20 ml each side) was used for the TAP block.) * Group 2: 20 ml bupivacaine+1ug/kg clonidine bilaterally (a total volume of 40 ml (20 ml each side) was used for the TAP * Group3: bupivacaine 0.25% + placebo (a total volume of 40 ml (20 ml each side) was used for the TAP A prospective Randomized Interventional double-blind study.
Detailed description
Women, following Caesarean delivery, have even more compelling reasons to receive optimal post-operative pain relief, for improved maternal and neonatal well-being. Also, adequate pain relief helps the patient to ambulate early and prevent any thrombotic incidents . Dexmedetomidine, an imidazole compound, is the pharmacologically active dextroisomer of medetomidine that displays specific and selective α 2-adrenoceptor agonist activity and causes sedation, analgesia without any delirium, or respiratory depression. The mechanism of action is unique and differs from those of currently used agents, including clonidine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bupivacaine | bupivacaine 0.25% a total volume of 40 ml (20 ml each side |
| DRUG | Dexmedetomidine | Dexmedetomidine 0.5 mcg/kg |
| DRUG | clonidine | 1ug/kg clonidine |
| DRUG | placebo | add placebo 9normal saline) |
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2020-06-30
- Completion
- 2020-08-01
- First posted
- 2018-12-10
- Last updated
- 2020-08-05
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03770013. Inclusion in this directory is not an endorsement.